FDA Announces Another Over-the-Counter Naloxone Nasal Spray Option
An FDA announcement says Rextovy, a 4-milligram naloxone nasal spray, can be sold without a prescription for opioid-overdose emergencies.
The short version
- What they foundFDA says Rextovy is an over-the-counter 4-milligram naloxone nasal spray.
- What it meansIt may offer another nonprescription option for overdose emergencies.
- What we don't know yetIts price, availability and differences from other sprays remain unknown.
The study at a glance
- Study type
- FDA regulatory announcement
The FDA announcement describes a new nonprescription option for responding to a suspected opioid overdose. Rextovy is a nasal spray containing 4 milligrams of naloxone hydrochloride. Naloxone is the standard medicine used to reverse the effects of an opioid overdose.
The FDA says Rextovy may be sold directly to consumers without a prescription. That could include pharmacies, convenience stores and online retailers. The agency granted the nonprescription approval to Amphastar Pharmaceuticals, Inc.
The product is intended for emergencies. Its packaging includes pictorial, or picture-based, instructions in five steps. The announcement says those directions include calling 911 after the first dose is given.
The FDA says naloxone can be used when it is uncertain whether opioids are in a person’s system. People who regain consciousness after an overdose reversal may have symptoms such as shaking, sweating, nausea or anger, the announcement says.
The agency presented the approval as one more way to broaden access to naloxone. It said having several approved products could expand supply, offer alternative sources and encourage competition. However, the release says competition may reduce costs; it does not provide evidence that prices have fallen or say what Rextovy will cost.
The announcement also cites provisional U.S. overdose-death figures. It reports 111,451 deaths in the 12 months ending in August 2023 and 68,632 deaths in the 12 months ending in December 2025. Those figures describe a change over time, but the release does not establish that over-the-counter naloxone caused the decline. Many factors can affect overdose deaths.
This announcement is not a completed clinical-study report. It does not provide a study design, participant number, comparison group, follow-up period or quantitative effectiveness results for Rextovy. It also does not show whether this product works differently from other approved naloxone nasal sprays, or whether it will be easier to find or afford in practice.
Before publication, the announcement’s date and regulatory claims should be independently verified. Based on the supplied material alone, the clearest takeaway is that the FDA describes Rextovy as an additional over-the-counter naloxone nasal spray option for opioid-overdose emergencies.
Why it matters
In an overdose emergency, speed matters. An additional nonprescription naloxone nasal spray could give consumers another way to obtain a medicine used to reverse opioid overdose.
What to keep in mind
The supplied material is an FDA announcement, not a clinical trial report. It does not show how Rextovy compares with other naloxone sprays on price, availability, safety or real-world outcomes.
Joi Frontier Health News shares hopeful, credible health information. It is not medical advice, diagnosis, or treatment — talk with a qualified healthcare professional about your situation. If you are in crisis or thinking about self-harm, contact your local emergency or crisis line.
Related
Fluoxetine and naltrexone showed similar results for compulsive sexual behavior disorder
In a small eight-week randomized trial, neither medication clearly outperformed the other, though symptom changes and side effects differed.
Menopausal changes at 46 linked with more anxiety and depression symptoms
In a Finnish cohort study, women already in the menopausal transition at age 46 reported anxiety and depression symptoms more often than peers not yet in transition.
Paper Urges Caution With AI Chatbots Used for Emotional Support
A new paper argues that warm, humanlike chatbots can blur the line between a digital tool and a relationship.
Study links childhood neglect with repeated suicide attempts in psychiatric inpatients
A study of 300 adult psychiatric inpatients found that childhood neglect, especially physical neglect, was associated with a history of repeated suicide attempts.
Comments
Comments here come from JoiApp readers.